Advocacy intelligence hub — real-time data for patient organizations
Astellas Pharma Global Development, Inc. — PHASE1, PHASE2
Radiopharm Theranostics, Ltd — PHASE1, PHASE2
Fate Therapeutics — PHASE1
Aromics Therapeutics — PHASE1
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Eli Lilly and Company — PHASE1
National Cancer Institute (NCI) — PHASE2
Universitaire Ziekenhuizen KU Leuven — PHASE2
AGO Research GmbH — PHASE2
BicycleTx Limited — PHASE1, PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Matthew Krebs, Dr
The Christie Hospital
Florence JOLY
Centre François Baclesse
Robert Maki, MD, PhD, MD, PhD
Memorial Sloan Kettering Cancer Center
📍 PHILADELPHIA, PA
Study Official
Genmab
Paul Martin
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Susan K. Parsons, MD, MRP
Tufts Medical Center Cancer Center
View all Malignant non-epithelial tumor of ovary specialists →